An improved method for the determination of fluticasone propionate in human plasma
Therapeutic monitoring of the potent, highly lipophilic glucocorticoid, fluticasone propionate (FP), was initially performed by a radioimmunoassay method. However an improved method with a lower limit of quantitation (LLOQ) of at least 25 pg per ml (pg ml −1) was needed to measure the low levels of...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmaceutical and biomedical analysis 1999-12, Vol.21 (4), p.749-758 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 758 |
|---|---|
| container_issue | 4 |
| container_start_page | 749 |
| container_title | Journal of pharmaceutical and biomedical analysis |
| container_volume | 21 |
| creator | Laugher, Lynn Noctor, Terry G Barrow, Andrew Oxford, Janet M Phillips, Trevor |
| description | Therapeutic monitoring of the potent, highly lipophilic glucocorticoid, fluticasone propionate (FP), was initially performed by a radioimmunoassay method. However an improved method with a lower limit of quantitation (LLOQ) of at least 25 pg per ml (pg ml
−1) was needed to measure the low levels of FP present in human plasma following inhalation administration of doses in the range 50–250 μg twice daily. A sensitive and specific liquid chromatographic, tandem mass spectrometric method (LC-MS/MS) with automated solid phase extraction (SPE) was developed and validated. Fluticasone propionate was extracted from plasma using Bond Elut C18 cartridges and analysed using reverse-phase chromatography with atmospheric pressure chemical ionisation followed by selective reaction monitoring. The method used a
13C-labelled internal standard and was validated over a concentration range of 25–500 pg ml
−1. The method was shown to be specific, sensitive and reliable in the analysis of clinical samples. The main advantages of this method over the radioimmunoassay method previously used were improved sensitivity, specificity, ease of sample preparation and shortened analysis time. |
| doi_str_mv | 10.1016/S0731-7085(99)00213-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69449155</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0731708599002137</els_id><sourcerecordid>69449155</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-327d52279627443e9ed2acdf7c4ba8ab1386a03818c90a3f5317d50ca3aa371f3</originalsourceid><addsrcrecordid>eNqFkF1rFTEQhoMo9lj9CUouRPRi62Szu9lclVL8gkKhKngX5iQTTmQ3e0yyhf57056DeufVDMPzzgwPYy8FnAkQw_uvoKRoFIz9W63fAbRCNuoR24hRyaYduh-P2eYPcsKe5fwTAHqhu6fsRICC2sGG3VxEHuZ9Wm7J8ZnKbnHcL4mXHXFHhdIcIpawRL547qe1BIt5icRrZF_HWIiHyHfrjJHvJ8wzPmdPPE6ZXhzrKfv-8cO3y8_N1fWnL5cXV42VGkojW-X6tlV6aFXXSdLkWrTOK9ttccStkOOAIEcxWg0ofS9FDYBFiSiV8PKUvTnsra_8WikXM4dsaZow0rJmM-iu06LvK9gfQJuWnBN5s09hxnRnBJh7meZBprk3ZbQ2DzKNqrlXxwPrdib3T-pgrwKvjwBmi5NPGG3If7kWdEUrdn7AqNq4DZRMtoGiJRcS2WLcEv7zyW96rJDX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69449155</pqid></control><display><type>article</type><title>An improved method for the determination of fluticasone propionate in human plasma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Laugher, Lynn ; Noctor, Terry G ; Barrow, Andrew ; Oxford, Janet M ; Phillips, Trevor</creator><creatorcontrib>Laugher, Lynn ; Noctor, Terry G ; Barrow, Andrew ; Oxford, Janet M ; Phillips, Trevor</creatorcontrib><description>Therapeutic monitoring of the potent, highly lipophilic glucocorticoid, fluticasone propionate (FP), was initially performed by a radioimmunoassay method. However an improved method with a lower limit of quantitation (LLOQ) of at least 25 pg per ml (pg ml
−1) was needed to measure the low levels of FP present in human plasma following inhalation administration of doses in the range 50–250 μg twice daily. A sensitive and specific liquid chromatographic, tandem mass spectrometric method (LC-MS/MS) with automated solid phase extraction (SPE) was developed and validated. Fluticasone propionate was extracted from plasma using Bond Elut C18 cartridges and analysed using reverse-phase chromatography with atmospheric pressure chemical ionisation followed by selective reaction monitoring. The method used a
13C-labelled internal standard and was validated over a concentration range of 25–500 pg ml
−1. The method was shown to be specific, sensitive and reliable in the analysis of clinical samples. The main advantages of this method over the radioimmunoassay method previously used were improved sensitivity, specificity, ease of sample preparation and shortened analysis time.</description><identifier>ISSN: 0731-7085</identifier><identifier>EISSN: 1873-264X</identifier><identifier>DOI: 10.1016/S0731-7085(99)00213-7</identifier><identifier>PMID: 10701940</identifier><identifier>CODEN: JPBADA</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Analysis ; Androstadienes - administration & dosage ; Androstadienes - blood ; Anti-Inflammatory Agents - blood ; Automated assay ; Biological and medical sciences ; Fluticasone ; Fluticasone propionate ; Gas Chromatography-Mass Spectrometry - methods ; General pharmacology ; Glucocorticoid ; Humans ; Mass spectrometry ; Medical sciences ; Pharmacology. Drug treatments ; Radioimmunoassay ; Reference Standards ; Reproducibility of Results</subject><ispartof>Journal of pharmaceutical and biomedical analysis, 1999-12, Vol.21 (4), p.749-758</ispartof><rights>1999 Elsevier Science B.V.</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-327d52279627443e9ed2acdf7c4ba8ab1386a03818c90a3f5317d50ca3aa371f3</citedby><cites>FETCH-LOGICAL-c390t-327d52279627443e9ed2acdf7c4ba8ab1386a03818c90a3f5317d50ca3aa371f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0731708599002137$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1209070$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10701940$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laugher, Lynn</creatorcontrib><creatorcontrib>Noctor, Terry G</creatorcontrib><creatorcontrib>Barrow, Andrew</creatorcontrib><creatorcontrib>Oxford, Janet M</creatorcontrib><creatorcontrib>Phillips, Trevor</creatorcontrib><title>An improved method for the determination of fluticasone propionate in human plasma</title><title>Journal of pharmaceutical and biomedical analysis</title><addtitle>J Pharm Biomed Anal</addtitle><description>Therapeutic monitoring of the potent, highly lipophilic glucocorticoid, fluticasone propionate (FP), was initially performed by a radioimmunoassay method. However an improved method with a lower limit of quantitation (LLOQ) of at least 25 pg per ml (pg ml
−1) was needed to measure the low levels of FP present in human plasma following inhalation administration of doses in the range 50–250 μg twice daily. A sensitive and specific liquid chromatographic, tandem mass spectrometric method (LC-MS/MS) with automated solid phase extraction (SPE) was developed and validated. Fluticasone propionate was extracted from plasma using Bond Elut C18 cartridges and analysed using reverse-phase chromatography with atmospheric pressure chemical ionisation followed by selective reaction monitoring. The method used a
13C-labelled internal standard and was validated over a concentration range of 25–500 pg ml
−1. The method was shown to be specific, sensitive and reliable in the analysis of clinical samples. The main advantages of this method over the radioimmunoassay method previously used were improved sensitivity, specificity, ease of sample preparation and shortened analysis time.</description><subject>Analysis</subject><subject>Androstadienes - administration & dosage</subject><subject>Androstadienes - blood</subject><subject>Anti-Inflammatory Agents - blood</subject><subject>Automated assay</subject><subject>Biological and medical sciences</subject><subject>Fluticasone</subject><subject>Fluticasone propionate</subject><subject>Gas Chromatography-Mass Spectrometry - methods</subject><subject>General pharmacology</subject><subject>Glucocorticoid</subject><subject>Humans</subject><subject>Mass spectrometry</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Radioimmunoassay</subject><subject>Reference Standards</subject><subject>Reproducibility of Results</subject><issn>0731-7085</issn><issn>1873-264X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkF1rFTEQhoMo9lj9CUouRPRi62Szu9lclVL8gkKhKngX5iQTTmQ3e0yyhf57056DeufVDMPzzgwPYy8FnAkQw_uvoKRoFIz9W63fAbRCNuoR24hRyaYduh-P2eYPcsKe5fwTAHqhu6fsRICC2sGG3VxEHuZ9Wm7J8ZnKbnHcL4mXHXFHhdIcIpawRL547qe1BIt5icRrZF_HWIiHyHfrjJHvJ8wzPmdPPE6ZXhzrKfv-8cO3y8_N1fWnL5cXV42VGkojW-X6tlV6aFXXSdLkWrTOK9ttccStkOOAIEcxWg0ofS9FDYBFiSiV8PKUvTnsra_8WikXM4dsaZow0rJmM-iu06LvK9gfQJuWnBN5s09hxnRnBJh7meZBprk3ZbQ2DzKNqrlXxwPrdib3T-pgrwKvjwBmi5NPGG3If7kWdEUrdn7AqNq4DZRMtoGiJRcS2WLcEv7zyW96rJDX</recordid><startdate>19991201</startdate><enddate>19991201</enddate><creator>Laugher, Lynn</creator><creator>Noctor, Terry G</creator><creator>Barrow, Andrew</creator><creator>Oxford, Janet M</creator><creator>Phillips, Trevor</creator><general>Elsevier B.V</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19991201</creationdate><title>An improved method for the determination of fluticasone propionate in human plasma</title><author>Laugher, Lynn ; Noctor, Terry G ; Barrow, Andrew ; Oxford, Janet M ; Phillips, Trevor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-327d52279627443e9ed2acdf7c4ba8ab1386a03818c90a3f5317d50ca3aa371f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Analysis</topic><topic>Androstadienes - administration & dosage</topic><topic>Androstadienes - blood</topic><topic>Anti-Inflammatory Agents - blood</topic><topic>Automated assay</topic><topic>Biological and medical sciences</topic><topic>Fluticasone</topic><topic>Fluticasone propionate</topic><topic>Gas Chromatography-Mass Spectrometry - methods</topic><topic>General pharmacology</topic><topic>Glucocorticoid</topic><topic>Humans</topic><topic>Mass spectrometry</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Radioimmunoassay</topic><topic>Reference Standards</topic><topic>Reproducibility of Results</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laugher, Lynn</creatorcontrib><creatorcontrib>Noctor, Terry G</creatorcontrib><creatorcontrib>Barrow, Andrew</creatorcontrib><creatorcontrib>Oxford, Janet M</creatorcontrib><creatorcontrib>Phillips, Trevor</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laugher, Lynn</au><au>Noctor, Terry G</au><au>Barrow, Andrew</au><au>Oxford, Janet M</au><au>Phillips, Trevor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An improved method for the determination of fluticasone propionate in human plasma</atitle><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle><addtitle>J Pharm Biomed Anal</addtitle><date>1999-12-01</date><risdate>1999</risdate><volume>21</volume><issue>4</issue><spage>749</spage><epage>758</epage><pages>749-758</pages><issn>0731-7085</issn><eissn>1873-264X</eissn><coden>JPBADA</coden><abstract>Therapeutic monitoring of the potent, highly lipophilic glucocorticoid, fluticasone propionate (FP), was initially performed by a radioimmunoassay method. However an improved method with a lower limit of quantitation (LLOQ) of at least 25 pg per ml (pg ml
−1) was needed to measure the low levels of FP present in human plasma following inhalation administration of doses in the range 50–250 μg twice daily. A sensitive and specific liquid chromatographic, tandem mass spectrometric method (LC-MS/MS) with automated solid phase extraction (SPE) was developed and validated. Fluticasone propionate was extracted from plasma using Bond Elut C18 cartridges and analysed using reverse-phase chromatography with atmospheric pressure chemical ionisation followed by selective reaction monitoring. The method used a
13C-labelled internal standard and was validated over a concentration range of 25–500 pg ml
−1. The method was shown to be specific, sensitive and reliable in the analysis of clinical samples. The main advantages of this method over the radioimmunoassay method previously used were improved sensitivity, specificity, ease of sample preparation and shortened analysis time.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>10701940</pmid><doi>10.1016/S0731-7085(99)00213-7</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0731-7085 |
| ispartof | Journal of pharmaceutical and biomedical analysis, 1999-12, Vol.21 (4), p.749-758 |
| issn | 0731-7085 1873-264X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69449155 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Analysis Androstadienes - administration & dosage Androstadienes - blood Anti-Inflammatory Agents - blood Automated assay Biological and medical sciences Fluticasone Fluticasone propionate Gas Chromatography-Mass Spectrometry - methods General pharmacology Glucocorticoid Humans Mass spectrometry Medical sciences Pharmacology. Drug treatments Radioimmunoassay Reference Standards Reproducibility of Results |
| title | An improved method for the determination of fluticasone propionate in human plasma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T05%3A11%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20improved%20method%20for%20the%20determination%20of%20fluticasone%20propionate%20in%20human%20plasma&rft.jtitle=Journal%20of%20pharmaceutical%20and%20biomedical%20analysis&rft.au=Laugher,%20Lynn&rft.date=1999-12-01&rft.volume=21&rft.issue=4&rft.spage=749&rft.epage=758&rft.pages=749-758&rft.issn=0731-7085&rft.eissn=1873-264X&rft.coden=JPBADA&rft_id=info:doi/10.1016/S0731-7085(99)00213-7&rft_dat=%3Cproquest_cross%3E69449155%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69449155&rft_id=info:pmid/10701940&rft_els_id=S0731708599002137&rfr_iscdi=true |